Gossamer Bio’s (GOSS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Gossamer Bio (NASDAQ:GOSS) in a research report report published on Tuesday morning, Benzinga reports. The firm currently has a $10.00 target price on the stock.

Several other research firms have also recently issued reports on GOSS. Wedbush restated an outperform rating and set a $4.00 target price on shares of Gossamer Bio in a research note on Tuesday, August 13th. Oppenheimer initiated coverage on shares of Gossamer Bio in a research report on Tuesday, June 25th. They set an outperform rating and a $9.00 price objective on the stock. Finally, The Goldman Sachs Group reaffirmed a buy rating and issued a $8.00 target price on shares of Gossamer Bio in a research report on Monday, June 17th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of Buy and an average target price of $9.20.

Gossamer Bio Price Performance

Shares of NASDAQ GOSS opened at $1.05 on Tuesday. The firm has a market cap of $237.53 million, a P/E ratio of -0.99 and a beta of 1.95. Gossamer Bio has a twelve month low of $0.45 and a twelve month high of $1.60. The company has a quick ratio of 8.21, a current ratio of 8.21 and a debt-to-equity ratio of 2.42. The company has a 50 day moving average of $0.93 and a 200 day moving average of $0.91.

Gossamer Bio (NASDAQ:GOSS) last posted its quarterly earnings results on Monday, August 12th. The company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.23 by ($0.01). The firm had revenue of $95.84 million during the quarter, compared to analysts’ expectations of $160.00 million. As a group, research analysts expect that Gossamer Bio will post -0.33 EPS for the current fiscal year.

Institutional Trading of Gossamer Bio

Several large investors have recently added to or reduced their stakes in GOSS. Sivia Capital Partners LLC bought a new position in Gossamer Bio in the first quarter worth approximately $29,000. SG Americas Securities LLC bought a new position in Gossamer Bio in the 1st quarter worth $34,000. Choreo LLC bought a new position in Gossamer Bio in the 2nd quarter worth $46,000. Algert Global LLC purchased a new position in Gossamer Bio during the second quarter valued at $75,000. Finally, Sequoia Financial Advisors LLC grew its holdings in Gossamer Bio by 27.2% during the second quarter. Sequoia Financial Advisors LLC now owns 93,500 shares of the company’s stock valued at $84,000 after purchasing an additional 20,000 shares during the period. 81.23% of the stock is currently owned by institutional investors.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.